Abstract: In neuropathic pain it has been suggested that pain phenotype based on putative pain mechanisms may predict response to treatment. This was a randomised, double-blind, placebo-controlled, and phenotype-stratified study with two 6-week treatment periods of oxcarbazepine (1800–2400mg) and placebo.